Literature DB >> 1629317

Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery.

M M Levine1, J McEwen, G Losonsky, M Reymann, I Harari, J E Brown, D N Taylor, A Donohue-Rolfe, D Cohen, M Bennish.   

Abstract

Acute- and convalescent-phase sera from 18 Thai patients and convalescent-phase sera from two Israeli patients and one Bangladeshi patient with Shigella dysenteriae 1 (Shiga) dysentery were tested by enzyme-linked immunosorbent assay to detect antibodies that bind S. dysenteriae lipopolysaccharide (LPS), Shiga holotoxin, or two synthetic peptides representing epitopes from the B subunit of Shiga toxin. Paired sera from 24 Maryland adults with Shigella flexneri 2a or Shigella sonnei diarrhea served as negative controls. Of the 16 paired Thai serum samples tested for immunoglobulin G LPS antibody, 10 had greater than or equal to 4-fold rises (the two subjects with the highest convalescent-phase titers exhibited toxin-neutralizing activity); acute-phase specimens from four of the remaining six individuals already had elevated Shiga LPS titers in their acute specimens ranging from 1:800 to 1:12,800. Similarly, convalescent-phase sera from the two Israeli patients and the Bangladeshi patient revealed LPS titers of 1:800 to 1:3,200. In contrast, none of the Maryland volunteers with S. flexneri or S. sonnei diarrhea manifested rises in Shiga anti-LPS (P less than 0.00001 versus 10 of 16 Thai patients). Only 4 of the 18 Thai patients had significant rise in antibody to purified Shiga toxin, while one of the two Israeli patients and the one Bangladeshi patient had elevated convalescent-phase titers. None of the sera that reacted with Shiga holotoxin had antibody that bound to the peptides. This report, which describes a search for serum antibodies that bind Shiga toxin in patients with Shiga dysentery, demonstrates such antibodies in only a minority of patients with bacteriologically confirmed disease. During Shiga dysentery, Shiga toxin may be elaborated in such small quantities in vivo that it fails to elicit an immune response in most patients even though it may exert biological effects. In this behavior Shiga toxin resembles tetanus toxin, another potent exotoxin that fails to elicit antitoxic responses in people who recover from clinical tetanus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1629317      PMCID: PMC265356          DOI: 10.1128/jcm.30.7.1636-1641.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  43 in total

1.  The action of the thermolabile toxin of Shigella dysenteriae on cells cultivated in vitro.

Authors:  G VICARI; A L OLITZKI; Z OLITZKI
Journal:  Br J Exp Pathol       Date:  1960-04

2.  Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1.

Authors:  A Fontaine; J Arondel; P J Sansonetti
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

3.  Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies.

Authors:  A Donohue-Rolfe; D W Acheson; A V Kane; G T Keusch
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

4.  Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Authors:  K L Kotloff; D A Herrington; T L Hale; J W Newland; L Van De Verg; J P Cogan; P J Snoy; J C Sadoff; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

5.  Synthetic peptides of Shiga toxin B subunit induce antibodies which neutralize its biological activity.

Authors:  I Harari; A Donohue-Rolfe; G Keusch; R Arnon
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

6.  Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes.

Authors:  N K Verma; A A Lindberg
Journal:  Vaccine       Date:  1991-01       Impact factor: 3.641

Review 7.  Shiga toxin: intestinal cell receptors and pathophysiology of enterotoxic effects.

Authors:  G T Keusch; M Jacewicz; M Mobassaleh; A Donohue-Rolfe
Journal:  Rev Infect Dis       Date:  1991 Mar-Apr

8.  Production of Shiga toxin and other cytotoxins by serogroups of Shigella.

Authors:  A V Bartlett; D Prado; T G Cleary; L K Pickering
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

9.  The relation between production of cytotoxin and clinical features in shigellosis.

Authors:  D Prado; T G Cleary; L K Pickering; C D Ericsson; A V Bartlett; H L DuPont; P C Johnson
Journal:  J Infect Dis       Date:  1986-07       Impact factor: 5.226

10.  Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease.

Authors:  A Cohen; V Madrid-Marina; Z Estrov; M H Freedman; C A Lingwood; H M Dosch
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

View more
  13 in total

1.  Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1.

Authors:  D Reymond; M A Karmali; I Clarke; M Winkler; M Petric
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

2.  Monoclonal antibody to Shiga toxin 2 which blocks receptor binding and neutralizes cytotoxicity.

Authors:  H Nakao; N Kiyokawa; J Fujimoto; S Yamasaki; T Takeda
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains.

Authors:  J R Butterton; E T Ryan; D W Acheson; S B Calderwood
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 4.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents.

Authors:  D Reymond; R P Johnson; M A Karmali; M Petric; M Winkler; S Johnson; K Rahn; S Renwick; J Wilson; R C Clarke; J Spika
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

6.  Biochemical, pathological and oncological relevance of Gb3Cer receptor.

Authors:  D Đevenica; V Čikeš Čulić; A Vuica; A Markotić
Journal:  Med Oncol       Date:  2010-11-11       Impact factor: 3.064

7.  Expression of A and B subunits of Shiga-like toxin II as fusions with glutathione S-transferase and their potential for use in seroepidemiology.

Authors:  F Gunzer; H Karch
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

8.  Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis.

Authors:  D Islam; B Wretlind; M Ryd; A A Lindberg; B Christensson
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

9.  Heterologous antigen expression in Vibrio cholerae vector strains.

Authors:  J R Butterton; D T Beattie; C L Gardel; P A Carroll; T Hyman; K P Killeen; J J Mekalanos; S B Calderwood
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

10.  Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1.

Authors:  M A Karmali; M Petric; M Winkler; M Bielaszewska; J Brunton; N van de Kar; T Morooka; G B Nair; S E Richardson; G S Arbus
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.